COVID-19
Therapeutic area
Infectious Disease
Rare disease
No
- Definition
- A disease caused by infection with severe acute respiratory syndrome coronavirus 2.
- Genetic basis
- No
- Non-human condition
- No
- Rare disease
- No
- Listing at source
- Listed
- Condition name
- COVID-19
- Therapeutic area
- Infectious Disease
- COVID-19
- 2019 novel coronavirus infection
- 2019-nCoV infection
- coronavirus disease 2019
- severe acute respiratory syndrome coronavirus 2 infectious disease
- 2019 novel coronavirus
- 2019-nCoV
- SARS-CoV-2
- SARS-coronavirus 2
- beta-CoV
- beta-CoVs
- betacoronavirus
- severe acute respiratory syndrome coronavirus 2
- β-CoV
- β-CoVs
- β-coronavirus
- Disease mechanisms
- Acquired
- All therapeutic areas
- Infectious Disease
- Severity
- Severe
- MONDO ID
- MONDO:0100096
- Parent condition
- MONDO:0020753
Related records
Broader conditions (10)
- Coronaviridae infectious disease
- Disease
- Disease by etiologic mechanism
- Disease of primarily extrinsic mechanism
- Human disease
- Infectious disease
- Nidovirales infectious disease
- Orthocoronavirinae infectious disease
- Primary viral infectious disease
- Viral infectious disease
Trials (7,802)
- '4C' Intervention to Reduce SARS-CoV-2 (Covid-19) Transmission
- 'Long COVID-19' in Suffolk and North Essex: Defining the Disease and Optimising Outcomes
- "Artificial Intelligence-Based Data Analysis Results and Mortality Prediction in Covid-19 Patients in Intensive Care"
- "Barotrauma in Admitted Covid-19 Cases - A Single Center Retrospective Study"
- "CHANGE COVID-19 Severity"
- "Clinical Characteristics, Comorbidities and Outcome of Critically Sick Patients With COVID-19
- "Efesovir" (FS-1) for COVID-19, Phase 2
- "Long COVID-19" on the Human Brain
- "Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of the Drug B10-FC After Single Administration to Adult Patients".
- "The Effect of Aerobic Exercise and Strength Training on Physical Activity Level, Quality of Life and Anxiety-Stress Disorder in Young Adults With and Without Covid-19"
- (CBDRA60) to Prevent or Reduce Symptoms of COVID-19 and Prevention of Post-Acute Sequelae of SARS-CoV-2 Infection PASC
- [14C] Study on Mass Balance and Biotransformation of STI-1558 in Healthy Chinese Adult Male Subjects
- [14C] Study to Investigate the Mass Balance and Biotransformation of WPV01 in Healthy Adult Chinese Male Participants
- [COVID-19] Reduction of Sars-CoV-2 Oral Viral Load With Prophylactic Mouth Rinse
- #SafeHandsSafeHearts: An eHealth Intervention for COVID-19 Prevention and Support
- #Stayhealthy - Monitoring and Maintenance of Mental Health Under Conditions of Social Isolation During the Corona Crisis
- #StayHome: Early Hydroxychloroquine to Reduce Secondary Hospitalisation and Household Transmission in COVID-19
- 1,3,7-Trimethylxanthine as a Treatment of COVID-19: Results of a Controlled Study
- 101-PGC-005 for the Treatment of COVID-19
- 2-year Mortality After COVID-19 in Nursing Home Residents
Approved drugs (12)
- Adenovirus type 26 encoding sars-cov-2 spike glycoprotein
- Anakinra
- Chimpanzee adenovirus encoding sars-cov-2 spike glycoprotein
- Elasomeran
- Regdanvimab
- Remdesivir
- Sars-cov-2 virus spike protein
- Sars-cov-2 virus, inactivated
- Selvacovatein
- Sotrovimab
- Tocilizumab
- Tozinameran
Drugs in development (548)
- .ALPHA.1-proteinase inhibitor human Phase 2
- 1018 ISS Phase 3
- 20-hydroxyecdysone Phase 2
- Abatacept Phase 3
- Abdavomeran Phase 2
- Abivertinib Phase 2
- Abivertinib maleate Phase 2
- Acalabrutinib Phase 3
- Acebilustat Phase 2
- Acetaminophen Phase 3
- Acetylcysteine Phase 3
- Acetylcysteine zidrimer Phase 2
- Acloproxalap Phase 2
- Adakitug Phase 2
- Adalimumab Phase 3
- Aderamastat Phase 1
- Adintrevimab Phase 2
- AG0302-COVID19 Phase 2
- Alanine Early phase 1
- Albendazole Phase 2
Other linked drugs (12)
- Aprotinin
- Calcium
- Copper
- Estrogen
- Fenofibrate
- Glutathione
- Hymecromone
- Lipoic acid, alpha
- Selenium
- Tetracycline
- Tetracycline hydrochloride
- Tramadol